ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunot…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

Updates in Combination Therapy for HCC

Yale Cancer Center

S. Stein

2023 AASLD Guidance for HCC

University of Texas Southwestern Medical Center

A. Singal

ESMO 2024 Summary: Highlights in HCC

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

Year in Review: Hepatobiliary Cancers

Moffitt Cancer Center

R. Kim, T. Biachi

Understanding HCC: Perspectives on Diagnosis, Risk Factors, and Trea…

Yale Cancer Center

A. Jaffe

Current Approach to Frontline Systemic Therapy for Advanced Hepatoce…

Lionel Kankeu Fonkoua

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - P…

2024 ESMO Annual Meeting Insights Hub

J. Llovet

ESMO 2024 Insights: CheckMate 9DW Expanded Analysis - Nivo + Ipi vs.…

2024 ESMO Annual Meeting Insights Hub

H. Karachiwala

ASCO® 2024 Summary: "HCC Highlights From the CheckMate 9DW and CARES…

2024 ASCO® Annual Meeting Insights Hub

A. Vogel

2L Systemic Therapy for Unresectable HCC

Lorenza Rimassa

HCC: Updates in Management

Stanford Medicine

R. Dhanasekaran

ESMO 2024 Summary: Updates in HCC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

H. Babiker

SIR 2023: Histotripsy - Technology and Clinical Evidence

SIR 2023 Conference Coverage

T. Ziemlewicz

Current Evidence for Frontline Systematic Treatment in Advanced HCC

Johns Hopkins

M. Baretti

Hepatic Hilar Nerve Block for Adjunctive Analgesia during Percutaneo…

Dennis Parhar

The Role of Adjuvant Therapy Following HCC Resection

Integrity CE

M. Baretti

SoC and Future Perspectives in Hepatocellular Cancer

Arndt Vogel

Evolving Options for the Treatment of HCC With IO and Liver-Directed…

The France Foundation

A. Smolock, B. George

Management of Toxicity and Dose Modification Associated With Cabozan…

Cedars Sinai

J. Gong